215 related articles for article (PubMed ID: 16928833)
1. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays.
Smith L; Watson MB; O'Kane SL; Drew PJ; Lind MJ; Cawkwell L
Mol Cancer Ther; 2006 Aug; 5(8):2115-20. PubMed ID: 16928833
[TBL] [Abstract][Full Text] [Related]
2. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.
Huang Y; Jiang D; Sui M; Wang X; Fan W
Oncol Rep; 2017 Feb; 37(2):705-712. PubMed ID: 28000875
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of microRNAs expressed in human breast cancer chemo-resistant MCF-7/Adr cells by Solexa deep-sequencing technology.
Xu P; Wang L; Huang L; Li W; Lv S; Lv M; Ma J; Zhou Q; Wu X; Fu Z; Lu C; Yin H
Biomed Pharmacother; 2015 Oct; 75():173-8. PubMed ID: 26293775
[TBL] [Abstract][Full Text] [Related]
5. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?
Hodgkinson VC; ELFadl D; Agarwal V; Garimella V; Russell C; Long ED; Fox JN; McManus PL; Mahapatra TK; Kneeshaw PJ; Drew PJ; Lind MJ; Cawkwell L
J Proteomics; 2012 Feb; 75(4):1276-83. PubMed ID: 22115752
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
Tormo E; Pineda B; Serna E; Guijarro A; Ribas G; Fores J; Chirivella E; Climent J; Lluch A; Eroles P
J Cell Biochem; 2015 Sep; 116(9):2061-73. PubMed ID: 25802200
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin resistance in breast cancer: A novel role for the human protein AHNAK.
Davis T; van Niekerk G; Peres J; Prince S; Loos B; Engelbrecht AM
Biochem Pharmacol; 2018 Feb; 148():174-183. PubMed ID: 29309757
[TBL] [Abstract][Full Text] [Related]
8. FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.
Xu M; Chen S; Yang W; Cheng X; Ye Y; Mao J; Wu X; Huang L; Ji J
Cell Physiol Biochem; 2018; 47(1):151-160. PubMed ID: 29763898
[TBL] [Abstract][Full Text] [Related]
9. Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization.
Guo B; Hembruff SL; Villeneuve DJ; Kirwan AF; Parissenti AM
Breast Cancer Res Treat; 2003 Nov; 82(2):125-41. PubMed ID: 14692656
[TBL] [Abstract][Full Text] [Related]
10. The trefoil factor 1 (TFF1) protein involved in doxorubicin‑induced apoptosis resistance is upregulated by estrogen in breast cancer cells.
Pelden S; Insawang T; Thuwajit C; Thuwajit P
Oncol Rep; 2013 Sep; 30(3):1518-26. PubMed ID: 23836323
[TBL] [Abstract][Full Text] [Related]
11. Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.
Aliabadi HM; Maranchuk R; Kucharski C; Mahdipoor P; Hugh J; Uludağ H
J Control Release; 2013 Nov; 172(1):219-228. PubMed ID: 23994345
[TBL] [Abstract][Full Text] [Related]
12. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.
Skildum A; Dornfeld K; Wallace K
Breast Cancer Res Treat; 2011 Oct; 129(3):785-97. PubMed ID: 21128112
[TBL] [Abstract][Full Text] [Related]
14. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
15. Resistance-associated signatures in breast cancer.
Györffy B
Recent Results Cancer Res; 2007; 176():37-50. PubMed ID: 17607915
[TBL] [Abstract][Full Text] [Related]
16. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
18. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.
Chekhun VF; Lukyanova NY; Burlaka CA; Bezdenezhnykh NA; Shpyleva SI; Tryndyak VP; Beland FA; Pogribny IP
Int J Oncol; 2013 Nov; 43(5):1481-6. PubMed ID: 23969999
[TBL] [Abstract][Full Text] [Related]
19. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
[TBL] [Abstract][Full Text] [Related]
20. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma.
Suzuki A; Toi M; Yamamoto Y; Saji S; Muta M; Tominaga T
Jpn J Cancer Res; 1998 Feb; 89(2):221-7. PubMed ID: 9548451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
